These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 28507339)
1. Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. Xiao J; Du S; Dai G; Gao G; Yang D; Zhao H Sci Rep; 2017 May; 7(1):1905. PubMed ID: 28507339 [TBL] [Abstract][Full Text] [Related]
2. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282 [TBL] [Abstract][Full Text] [Related]
3. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411 [TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843 [TBL] [Abstract][Full Text] [Related]
5. A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma. Kassam S; Bower M; Lee SM; de Vos J; Fields P; Gandhi S; Nelson M; Montoto S; Tenant-Flowers M; Burns F; Marcus R; Edwards SG; Cwynarski K Leuk Lymphoma; 2013 Sep; 54(9):1921-7. PubMed ID: 23206228 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006 [TBL] [Abstract][Full Text] [Related]
7. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018 [TBL] [Abstract][Full Text] [Related]
8. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075 [TBL] [Abstract][Full Text] [Related]
9. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468 [TBL] [Abstract][Full Text] [Related]
10. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras. Vähämurto P; Mannisto S; Pollari M; Karjalainen-Lindsberg ML; Mäkitie AA; Leppä S Eur J Haematol; 2019 Jun; 102(6):457-464. PubMed ID: 30834564 [TBL] [Abstract][Full Text] [Related]
11. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919 [TBL] [Abstract][Full Text] [Related]
12. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644 [TBL] [Abstract][Full Text] [Related]
13. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Boslooper K; Kibbelaar R; Storm H; Veeger NJ; Hovenga S; Woolthuis G; van Rees B; de Graaf E; van Roon E; Kluin-Nelemans HC; Joosten P; Hoogendoorn M Leuk Lymphoma; 2014 Mar; 55(3):526-32. PubMed ID: 23734653 [TBL] [Abstract][Full Text] [Related]
14. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120 [TBL] [Abstract][Full Text] [Related]
16. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. Wong AY; Marcotte S; Laroche M; Sheehan NL; Kukreti V; Routy JP; Lemieux B; Seki JT; Rouleau D; Tseng A Antivir Ther; 2013; 18(5):699-707. PubMed ID: 23640963 [TBL] [Abstract][Full Text] [Related]
19. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819 [TBL] [Abstract][Full Text] [Related]
20. Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. van de Schans SAM; Wymenga ANM; van Spronsen DJ; Schouten HC; Coebergh JWW; Janssen-Heijnen MLG Ann Oncol; 2012 May; 23(5):1280-1286. PubMed ID: 21948810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]